Lansoprazole, levofloxacin and amoxicillin triple therapy vs. quadruple therapy as second‐line treatment of resistant <i>Helicobacter pylori</i> infection

Wong, Wai‐Man; Gu, Qing; Chu, Kent‐Man; Yee, Y. K.; Fung, F. M. Y.; Tong, Teresa; Chan, Annie On‐On; Lai, KC; Chan, Chi Kuen; Wong, Bcy

doi:10.1111/j.1365-2036.2006.02764.x

Cited by 58 publications

(63 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Moreover, two metaanalyses have demonstrated a lower incidence of adverse effects with levofloxacin-based treatments than with the quadruple combinations [88,89] . Unfortunately, it has been shown that resistance to quinolones is easily acquired, and in countries with a high consumption of these drugs, the resistance rate is increasing and is already relatively high [94,103,107,[113][114][115][116][117][118][119][120][121][122][123] . More importantly, it has been demonstrated that the presence of levofloxacin resistance significantly reduce the eradication rate following a therapy with this antibiotic [94,103,121,124] .…”

Section: Rbc Tetracycline and Metronidazolementioning

confidence: 99%

“Rescue” regimens after Helicobacter pylori treatment failure

Gisbert¹

2008

WJG

View full text Add to dashboard Cite

Helicobacter pylori (H pylori ) infection is the main cause of gastritis, gastroduodenal ulcer disease, and gastric cancer. After more than 20 years of experience in H pylori treatment, in my opinion, the ideal regimen to treat this infection is still to be found. Currently, apart from having to know first-line eradication regimens well, we must also be prepared to face treatment failures. Therefore, in designing a treatment strategy we should not focus on the results of primary therapy alone, but also on the final (overall) eradication rate. The choice of a "rescue" treatment depends on which treatment is used initially. If a clarithromycinbased regimen was used initially, a subsequent metronidazole-based treatment (quadruple therapy) may be used afterwards, and then a levofloxacinbased combination would be a third "rescue" option. Alternatively, it has recently been suggested that levofloxacin-based rescue therapy constitutes an encouraging second-line strategy, representing an alternative to quadruple therapy in patients with previous PPI-clarithromycin-amoxicillin failure, with the advantage of efficacy, simplicity and safety. In this case, a quadruple regimen may be reserved as a third-line rescue option. Finally, rifabutin-based rescue therapy constitutes an encouraging empirical fourthline strategy after multiple previous eradication failures with key antibiotics such as amoxicillin, clarithromycin, metronidazole, tetracycline, and levofloxacin. Even after two consecutive failures, several studies have demonstrated that H pylori eradication can finally be achieved in almost all patients if several rescue therapies are consecutively given. Therefore, the attitude in H pylori eradication therapy failure, even after two or more unsuccessful attempts, should be to fight and not to surrender.

show abstract

Section: Rbc Tetracycline and Metronidazolementioning

confidence: 99%

“Rescue” regimens after Helicobacter pylori treatment failure

Gisbert¹

2008

WJG

View full text Add to dashboard Cite

show abstract

“…The first-line regimen continues to have a 10%-23% failure rate [5][6][7][8][9][10] . Unfortunately, several studies have shown that rescue regimens have failed in 5%-63% of patients whose H pylori cannot be eradicated by standard PPI-based triple therapies [11,12] .…”

Section: Introductionmentioning

confidence: 99%

Short-term Celecoxib intervention is a safe and effective chemopreventive for gastric carcinogenesis based on a Mongolian gerbil model

Kuo¹,

Hu²,

Tsai³

et al. 2009

WJG

View full text Add to dashboard Cite

AIM:To evaluate the optimal intervention point of a selective cyclooxygenase-2 (COX-2) inhibitor, Celecoxib, for inhibiting Helicobacter pylori (H pylori )-associated gastric carcinogenesis in Mongolian gerbils (MGs). METHODS:One hundred and twelve MGs were divided into six groups (A-F). One hundred gerbils were inoculated with H pylori (groups A-E). Twelve gerbils were inoculated with vehicle broth only (group F). After 4 wk, they were given N'-methyl-N' -nitro-N-nitroso-guanidine (MNNG) (50 mg/mL) in the drinking water for 20 wk. In groups B-E, the animals were given the stock Celecoxib (10 mg/kg per day) diet from the 21st, 31st, 21st and 41st week respectively. The periods of administering Celecoxib were 30, 20, 20, and 15 wk respectively. On the 51st week, the animals were sacrificed for histological examination. Local PCNA expression was examined by the immunohistochemistry method. The expression of COX-2 protein was assessed by Western Blot. Analysis used the χ 2 test. The difference was regarded as significant when P value was less than 0.05. RESULTS:Seventeen percent (17/100) of H pyloriinfected MGs developed gastric cancer. All of these lesions were well-differentiated adenocarcinoma. The incidence rates of adenocarcinoma in groups A-F were 40%, 0%, 0%, 20%, 25%, and 0% respectively. The inflammatory scores were higher in group B than in other groups. There was no inflammatory response noted in group F. Celecoxib treatment resulted in a significant reduction in the proliferation of H pyloriinfected mucosal cells (groups B, C and D) (P < 0.01). The expression of COX-2 protein was significantly attenuated in the groups which were Celecoxib-treated for more than 20 wk (groups B, C, D). The groups treated with Celecoxib had a significantly lower rate of advanced gastric cancer (34% vs 75%, P < 0.001)There were no sudden deaths in any of the groups. CONCLUSION:Short-term treatment with Celecoxib has an anti-carcinogenic effect, and resulted in less severe inflammation and inhibited the invasive degree of gastric cancer.

show abstract

“…Levofloxacin therapy is superior efficacy than triple therapy study in the US and it is the best treatment for H. pylori antibiotic resistance infected patients, especially metronidazole resistance (76%) and clarithromycin resistance (71%). In a recent study exposed that eradication rate is 90-92% for levofloxacin plus rabeprazole and either amoxicillin or tinidazole in a pilot study from Italy (Nicholas et al, 2014;Wong et al, 2006).…”

Section: Levofloxacin Therapymentioning

confidence: 99%

“…It is an appropriate therapeutic approach against H. pylori when sequential therapy failed (Zullo et al, 2006). Levofloxacin therapy cure rate is superior to quadruple therapy; it is shown that the eradication rate greater than 90% compared to quadruple therapy with a lower incidence of side effects (Wong et al, 2006;Ierardi et al, 2015).…”

Section: Levofloxacin Therapymentioning

confidence: 99%

Current Status of H. pylori Infection Treatment 2017

2017

J App Pharm Sci

View full text Add to dashboard Cite

H. pylori infection is highly associated with main symptoms and death that are recently affecting 50-75% of the population in the world. But past few years' efforts, H. pylori treatment is more difficult and it is still standing challenges for medical practitioner due to antibiotic resistance and patient compliance, as there are no regimens can achieve the desired eradication rate. In fact, no new drug has been developed for H. pylori only using different mixtures of antibiotics and anti-secretory agents. Nowadays, antibiotics are frequently prescribed for this infection that is declining their effectiveness as a result of which growing antibiotic resistant worldwide. At present, standard therapy has been regarded as the first line treatment of H. pylori in many guidelines, but the eradication rate has decreased to unacceptable levels. Therefore, standard triple therapy is left due to increase in antibiotic resistance consequences low eradication rate. Alternative treatment regimens such as sequential, quadruple, concomitant, and levofloxacin therapies are most recommended eradicating H. pylori compare to triple therapy; one of them levofloxacin therapy is most excellent therapy for eradicating H. pylori infection in antibiotic resistant patients. Herein, this review discussed recent data focusing on diverse eradication regimens so as to emphasize the current H. pylori treatment and the significance of considering the occurrence of antibiotic resistance at a regional level when choosing a suitable therapy.

show abstract

Lansoprazole, levofloxacin and amoxicillin triple therapy vs. quadruple therapy as second‐line treatment of resistant Helicobacter pylori infection

Cited by 58 publications

References 30 publications

“Rescue” regimens after Helicobacter pylori treatment failure

“Rescue” regimens after Helicobacter pylori treatment failure

Short-term Celecoxib intervention is a safe and effective chemopreventive for gastric carcinogenesis based on a Mongolian gerbil model

Current Status of H. pylori Infection Treatment 2017

Contact Info

Product

Resources

About